Search
PLT012
go.drugbank.com/drugs/DB23610InvestigationalPLT012 is a humanized anti-CD36 antibody developed by Pilatus Biosciences for treating liver cancer and intrahepatic bile duct cancer.
Linvencorvir
go.drugbank.com/drugs/DB21544InvestigationalLinvencorvir is under investigation in clinical trial NCT04225715 (A Trial To Evaluate The Efficacy And Safety Of Multiple Combination Therapies In Participants With Chronic Hepatitis B).
Relutrigine
go.drugbank.com/drugs/DB21614InvestigationalRelutrigine is under investigation in clinical trial NCT07010471 (A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine).
Orbifloxacin
go.drugbank.com/drugs/DB11443ExperimentalVet approvedIt is marketed by Schering-Plough Animal Health and approved for certain infections in dogs.
DLO6002
go.drugbank.com/drugs/DB05179ExperimentalDLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.
Gantacurium
go.drugbank.com/drugs/DB05710InvestigationalIt is being developed by Avera Pharmaceuticals.
Domofenogene zalfaparvovec
go.drugbank.com/drugs/DB16810InvestigationalDomofenogene zalfaparvovec, formerly known as BMN-307, is an investigational AAV5-phenylalanine hydroxylase (PAH) gene therapy developed by BioMarin Pharmaceutical.
NCX 1015
go.drugbank.com/drugs/DB05825ExperimentalNCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.